{"data":{"responsecode":"000","responsemsg":"","quote":{"hi":"56.850","rs_stock_flag":false,"fiscal_year_end":"2025年12月31日","hist_closedate":"2025年9月25日","replication_method":null,"amt_os":"279,164,339","primaryexch":"香港交易所","ric":"2565.HK","product_subtype":null,"db_updatetime":"2025年9月28日08:06","mkt_cap_u":"B","am_u":"M","ew_sub_right":"","secondary_listing":false,"ew_amt_os_cur":null,"ccy":"HKD","management_fee":"","ew_underlying_code":null,"trdstatus":"N","nav":"","original_offer_price":"","issue":"","asset_class":null,"eps":null,"inline_upper_strike_price":"","sedol":"BRJG4V6","am":"11.26","iv":"","ew_strike":"","as":"55.050","geographic_focus":null,"incorpin":"中華人民共和國","etp_baseCur":null,"ew_amt_os":"","bd":"54.600","registrar":"香港中央證券登記有限公司","depositary":null,"exotic_type":null,"callput_indicator":null,"primary_market":null,"underlying_index":null,"lot":"500","update_time":"2025-09-28 00:06:03.0","lo52":"8.680","shares_issued_date":"2025年8月31日","premium":"","strike_price_ccy":null,"yield":"","vo_u":"K","base_currency":null,"coupon":"","expiry_date":"","chairman":"Michael Min Xu","underlying_ric":"2565.HK","hi52":"57.700","issuer_name":"派格生物醫藥(杭州)股份有限公司 - B - H股","h_share_flag":false,"ew_sub_per_from":"","div_yield":"","interest_payment_date":"-","updatetime":"2025年9月26日15:58","aum_date":"","lo":"54.200","mkt_cap":"15.35","f_aum_hkd":null,"ew_sub_per_to":"","ls":"55.000","nav_date":"","csic_classification":null,"floating_flag":false,"issued_shares_note":null,"nom_ccy":null,"eff_gear":"","board_lot_nominal":null,"hsic_ind_classification":"醫療保健業 - 藥品及生物科技","ew_desc":null,"inception_date":"","nc":"-0.900","aum":"","issued_shares_class_B":null,"vo":"204.50","secondary_listing_flag":false,"listing_date":"2025年5月27日","issued_shares_class_A":null,"as_at_label":"截至","ew_amt_os_dat":"","nm":"派格生物醫藥(杭州)股份有限公司 - B - H股","nm_s":"派格生物醫藥－Ｂ","sym":"2565","inline_lower_strike_price":"","listing_category":"主要上市","ew_strike_cur":null,"exotic_warrant_indicator":null,"investment_focus":null,"call_price":"","tck":"0.050","strike_price":"","summary":"派格生物醫藥（杭州）股份有限公司是一家主要從事研究及開發慢性病創新療法的中國公司。該公司的主要產品PB-119是自主開發、接近商業化階段的長效胰高血糖素樣肽1（GLP-1，一種降低血糖水平的肽類激素）受體激動劑。該公司的候選產品包括PB-718、PB-1902、PB-722、PB-2301和PB-2309。該公司的產品主要用於治療2型糖尿病（T2DM）、肥胖症、非酒精性脂肪性肝炎（NASH）、阿片類藥物引起的便秘（OIC，使用阿片類藥物引起的胃腸道疾病）及先天性高胰島素血症（一種罕見的內分泌疾病，患者持續出現低血糖症）等常見慢病及代謝疾病。","op":"56.500","aum_u":"","nav_ccy":null,"class_B_description":null,"os":"","wnt_gear":"","transfer_of_listing_date":"","hsic_sub_sector_classification":"生物技術","amt_ccy":null,"class_A_description":null,"domicile_country":null,"entitlement_ratio":"","product_type":"EQTY","office_address":"中國浙江省<br/>杭州市拱墅區<br/>皓章大廈<br/>1幢606室","pc":"-1.61","days_to_expiry":null,"underlying_code":null,"pe":"","eps_ccy":null,"hdr":false,"launch_date":"","hc":"55.900","isin":"CNE100006T44","moneyness":""}},"qid":"1759074373817"}
